News › Industry News, Patient Care

WHO Identifies Falsified Batch Numbers in Medical Product Alert N°2/2024: Falsified Ozempic (semaglutide)

July 12, 2024
Injection pens

The World Health Organization (WHO) released a Medical Product Alert describing three falsified batches of Ozempic that were detected in Brazil, the U.K. and the U.S. in 2023. Ozempic’s manufacturer, Novo Nordisk, confirmed for the WHO that the products detected has misrepresented their identity and source, and where not manufactured by Novo Nordisk. The false identifiers are as follows:

  • Batch number LP6F832 is not recognized.
  • The combination of batch number NAR0074 with serial number 430834149057 does not correspond to genuine manufacturing records.
  • Batch number MP5E511 is genuine, but the product is falsified.

Health care professionals are encouraged to report adverse effects, lack of effectiveness and suspected falsification to the National Regulatory Authorities/National Pharmacovigilance Centre.

Read the full alert at World Health Organization >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Compounded Tirzepatide, NAD+ Injections Recalled Nationwide Over Sterility Concerns
    • Meliora Consulting Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations
    • Galderma to Acquire ZO Skin Health for $1.5 Billion
Advertisement